{"id":"NCT03573817","sponsor":"Mylan Inc.","briefTitle":"A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD","officialTitle":"A Phase 3b, 42-day, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Nebulized Revefenacin and Nebulized Formoterol Fumarate (PERFOROMIST®) Administered in Sequence and as a Combined Solution in Subjects With Chronic Obstructive Pulmonary Disease","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-31","primaryCompletion":"2018-09-25","completion":"2018-09-25","firstPosted":"2018-06-29","resultsPosted":"2019-12-18","lastUpdate":"2022-02-24"},"enrollment":122,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Obstructive Pulmonary Disease (COPD)"],"interventions":[{"type":"DRUG","name":"Revefenacin","otherNames":["TD-4208"]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Formoterol","otherNames":[]}],"arms":[{"label":"Period 1: Revefenacin + Formoterol (Sequential)","type":"EXPERIMENTAL"},{"label":"Period 2: Revefenacin + Formoterol (Combo Solution)","type":"EXPERIMENTAL"},{"label":"Period 1: Placebo + Formoterol (Sequential)","type":"PLACEBO_COMPARATOR"},{"label":"Period 2: Placebo + Formoterol (Combo Solution)","type":"PLACEBO_COMPARATOR"}],"summary":"The primary objective of the study was to characterize the safety and tolerability of once-daily revefenacin inhalation solution when dosed sequentially with twice-daily formoterol inhalation solution (PERFOROMIST®) compared to PERFOROMIST®, in a population of participants with moderate-to-very severe Chronic Obstructive Pulmonary Disease (COPD) over 21 days.","primaryOutcome":{"measure":"Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event","timeFrame":"Day 1 to End of Period 2, a Maximum of 42 days + 7 days follow-up (Each period was 21 days)","effectByArm":[{"arm":"Period 1: Revefenacin + Formoterol (Sequential)","deltaMin":7,"sd":null},{"arm":"Period 2: Revefenacin + Formoterol (Combo Solution)","deltaMin":6,"sd":null},{"arm":"Period 1: Placebo + Formoterol (Sequential)","deltaMin":3,"sd":null},{"arm":"Period 2: Placebo + Formoterol (Combo Solution)","deltaMin":5,"sd":null}],"pValues":[]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":4},"locations":{"siteCount":12,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":59},"commonTop":["Chronic obstructive pulmonary disease","Cough","Oropharyngeal pain","Dizziness","Sputum purulent"]}}